1
Burkhard Goke, Christoph Beglinger, Thomas R Coolidge: Human appetite control by glucagon-like peptide receptor binding compounds. Amylin Pharmaceuticals, Arnold & Porter, February 14, 2006: US06998387 (59 worldwide citation)

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by admini ...


2
Nigel Robert Arnold Beeley, Sunil Bhavsar: Use of exendins for the reduction of food intake. Amylin Pharmaceuticals, Arnold & Porter, October 18, 2005: US06956026 (58 worldwide citation)

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are usefu ...


3
Andrew A Young, Bronislava Gedulin, Nigel Robert Arnold Beeley, Kathryn S Prickett: Methods for regulating gastrointestinal motility. Amylin Pharmaceuticals, Arnold & Porter, February 22, 2005: US06858576 (53 worldwide citation)

Methods for reducing gastric motility and delaying gastric emptying for therapeutic and diagnostic purposes are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist. Methods for treating conditions associated with elevated, inappropriate, or undesired po ...


4
Richard A Hiles, Kathryn S Prickett: Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus. Amylin Pharmaceuticals, Brobeck Phleger & Harrison, January 14, 2003: US06506724 (52 worldwide citation)

Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels.


5
Andrew A Young, Bronislava Gedulin: Methods for glucagon suppression. Amylin Pharmaceuticals, Arnold & Porter, March 29, 2005: US06872700 (49 worldwide citation)

Methods for use of an exendin, an exendin agonist, or a modified exendin or exendin agonist having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, for lowering glucagon levels and/or suppressing glucagon secretion in a subject are provide. These methods ...


6
Kathryn S Prickett, Andrew A Young: Modified exendins and exendin agonists. Amylin Pharmaceuticals, Arnold & Porter, August 2, 2005: US06924264 (49 worldwide citation)

Novel modified exendins and exendin agonist analogs having an exendin or exendin agonist analog linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods of administration thereof are provided. These modified exendins and exendin agonist analog ...


7
Thomas R Coolidge, Mario Ehlers: Treatment of acute coronary syndrome with GLP-1. Amylin Pharmaceuticals, Molly A Holman, Mi K Kim, Arnold & Porter, March 16, 2004: US06706689 (48 worldwide citation)

The invention relates to methods for treating a patient suffering from acute coronary syndrome, but who is not suffering from a Q-wave myocardial infarction, comprising administration of a therapeutically effective amount of a GLP-1 molecule. The GLP-1 can be self-administered, and can be administer ...


8
Kevin Beaumont, Timothy J Rink: Receptor-based screening methods for amylin agonists and antagonists. Amylin Pharmaceuticals, Lyon & Lyon, November 23, 1993: US05264372 (46 worldwide citation)

Methods for identifying or screening or characterizing or assaying or isolating known or candidate agonists and antagonists of amylin, comprising binding assays utilizing preparations containing specific receptors for amylin. Membranes from the brain that contain high density receptors for amylin ar ...


9
Orville G Kolterman, Andrew A Young: Exendin agonist formulations and methods of administration thereof. Amylin Pharmaceuticals, Arnold & Porter, June 7, 2005: US06902744 (45 worldwide citation)

Novel exendin and exendin agonist compound formulations and dosages and methods of administration thereof are provided. These compositions and methods are useful in treating diabetes and conditions that would be benefited by lowering plasma glucose or delaying and/or slowing gastric emptying or inhi ...


10
Laura S L Gaeta, Howard Jones, Elisabeth Albrecht: Amylin agonist peptides and uses therefor. Amylin Pharmaceuticals, Lyon & Lyon L, November 11, 1997: US05686411 (43 worldwide citation)

Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.